+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metabolic Disorders - Disease & Epidemiology Overview

  • ID: 4705742
  • Report
  • July 2018
  • Region: Global
  • 55 pages
  • Decision Resources Group
1 of 3

FEATURED COMPANIES

  • Alnylam
  • GSK
  • Ionis/Akcea
  • Janssen and Genmab
  • Pfizer
  • Takeda
  • MORE
The Metabolic Disorders Disease & Epidemiology Overview report provides disease market overviews and global epidemiology overviews for 10 indications in the
Metabolic Disorders therapy area:Acromegaly,
Amyloidosis, Dyslipidemia, Gout, Non-alcoholic Steatohepatitis, Obesity/Overweight, Osteoporosis, Primary Biliary Cholangitis, Type 1 Diabetes and Type 2 Diabetes Disease. This report provides a disease market overview for each indication and global epidemiology overviews for each indication.

The disease market overviews include information such as market size forecasts, prevailing treatment trend analysis and predictions, key areas of unmet need, current and emerging therapies, physician (KOL) insights, clinical pipeline analysis, and more, for each indication. The global epidemiology overviews provide insights including global diagnosed prevalence, diagnosed prevalence by region, 10-year diagnosed prevalence growth forecast, relative sizes of the factors contributing to the trend in prevalent cases, and more, for each indication.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alnylam
  • GSK
  • Ionis/Akcea
  • Janssen and Genmab
  • Pfizer
  • Takeda
  • MORE
  • About the Analyst
  • About the analyst's Epidemiology
  • Disease Landscape and Insight Overview
  • Epidemiology Overview
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer
  • Alnylam
  • Ionis/Akcea
  • Takeda
  • Janssen and Genmab
  • GSK
Note: Product cover images may vary from those shown
Adroll
adroll